中外医学研究
中外醫學研究
중외의학연구
CHINESE AND FOREIGN MEDICAL RESEARCH
2014年
15期
39-39,40
,共2页
妊娠期高血压疾病%血管内皮生长因子%胎盘生长因子
妊娠期高血壓疾病%血管內皮生長因子%胎盤生長因子
임신기고혈압질병%혈관내피생장인자%태반생장인자
Hypertensive disorders in pregnancy%Vascular endothelial growth factor%Placental growth factor
目的:研究妊娠期高血压疾病患者血液指标变化的临床指导价值。方法:将2012年3月-2013年6月笔者所在医院收治的妊娠期高血压疾病患者纳入观察组,同期在笔者所在医院接受产前检查的健康孕妇纳入对照组,检测两组产妇的血液指标血管内皮生长因子(VEGF)和胎盘生长因子(PLGF)的含量,并分析其与血压水平的相关性。结果:(1)观察组产妇血液中VEGF和PLGF的含量均低于对照组;(2)血液中VEGF和PLGF的含量与收缩压、舒张压水平呈负相关。结论:妊娠期高血压疾病产妇的血液中VEGF和PLGF含量降低,且与血压水平呈现较好的相关性,具有积极的临床指导价值。
目的:研究妊娠期高血壓疾病患者血液指標變化的臨床指導價值。方法:將2012年3月-2013年6月筆者所在醫院收治的妊娠期高血壓疾病患者納入觀察組,同期在筆者所在醫院接受產前檢查的健康孕婦納入對照組,檢測兩組產婦的血液指標血管內皮生長因子(VEGF)和胎盤生長因子(PLGF)的含量,併分析其與血壓水平的相關性。結果:(1)觀察組產婦血液中VEGF和PLGF的含量均低于對照組;(2)血液中VEGF和PLGF的含量與收縮壓、舒張壓水平呈負相關。結論:妊娠期高血壓疾病產婦的血液中VEGF和PLGF含量降低,且與血壓水平呈現較好的相關性,具有積極的臨床指導價值。
목적:연구임신기고혈압질병환자혈액지표변화적림상지도개치。방법:장2012년3월-2013년6월필자소재의원수치적임신기고혈압질병환자납입관찰조,동기재필자소재의원접수산전검사적건강잉부납입대조조,검측량조산부적혈액지표혈관내피생장인자(VEGF)화태반생장인자(PLGF)적함량,병분석기여혈압수평적상관성。결과:(1)관찰조산부혈액중VEGF화PLGF적함량균저우대조조;(2)혈액중VEGF화PLGF적함량여수축압、서장압수평정부상관。결론:임신기고혈압질병산부적혈액중VEGF화PLGF함량강저,차여혈압수평정현교호적상관성,구유적겁적림상지도개치。
Objective:To study the clinical value of blood parameters change in patients with hypertensive disorders in pregnancy.Method:Patients with hypertensive disorders in pregnancy from March 2012 to June 2013 in our hospital were selected as observation group,at the same period in our hospital healthy pregnant woman were selected as control group,maternal blood indicators of vascular endothelial growth factor (VEGF) and placental growth factor (PLGF) levels were detected,and to analyze its correlation with blood pressure levels.Result:(1)Maternal blood levels of VEGF and PLGF were lower in the observation group than that in the control group.(2)There was negative correlation between the blood levels of VEGF,PLGF and the levels of systolic blood pressure,diastolic blood pressure.Conclusion:Blood levels of VEGF and PLGF reduce in patients with hypertensive disorders in pregnancy is low,and it shows good correlation with blood pressure levels.There is a positive clinical guidance value.